Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway
Harshika Khaim Chandani, Syeda Fadak Zahra Hujjat, Devya Khaim Chandani, Muhammad Saad Khan, Abubakr Mahmoud · 2026
Read Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway by Harshika Khaim Chandani, Syeda Fadak Zahra Hujjat, Devya Khaim Chandani, Muhammad Saad Khan, Abubakr Mahmoud (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13354454.txt.
Description
Harshika Khaim Chandani and others surveyed garadacimab, a new preventive care for hereditary angioedema, in 2026. This rare inherited illness causes recurrent, maybe life-risky swelling of skin, gut, and airway driven by bradykinin. Current preventive options help many people, but a more convenient and effective choice was still needed.
Approved by the United States Food and Drug Administration in June 2024, garadacimab is a first-in-class antibody that blocks activated Factor XII, acting upstream in the kallikrein-bradykinin pathway. By intervening earlier in the cascade, it aims to prevent attacks before swelling starts. The review helps doctors and people judge where this upstream approach fits among current prophylaxis options.
Catalog record
| CREATOR | Harshika Khaim Chandani, Syeda Fadak Zahra Hujjat, Devya Khaim Chandani, Muhammad Saad Khan, Abubakr Mahmoud |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |